About the Company: Core Business Segments
Founded in 1993 by the Kelkar family, Hexagon Nutrition has transformed from a domestic micro-formulations supplier into a highly integrated, research-driven product platform. The business fundamentally operates across three highly diversified global channels:
- B2B Food Fortification (Premixes): The company acts as an industrial anchor, blending specialized vitamins and minerals for major Indian and multi-national FMCG giants to fortify everyday consumer goods.
- B2C Branded Wellness: Hexagon manufactures and markets its own clinical nutrition brands directly to medical retail channels and e-commerce platforms. Key clinical portfolios include Pentasure (metabolic wellness), Obesigo (weight management), and Pediagold (pediatric nutrition).
- ESG & Humanitarian Aid: Recognized globally, the company manufactures Ready-to-Use Therapeutic Foods (RUTF) and Micronutrient Powders (MNPs) deployed under specialized United Nations global nutrition initiatives to eradicate acute malnutrition across developing regions.
The company commands a strong international footprint, exporting formulations to more than 75 countries across Europe, Asia, Africa, and South America, with operational manufacturing lines spread across Maharashtra, Tamil Nadu, and Uzbekistan.
Deep-Dive: Core Financial Trends
Hexagon Nutrition demonstrates an exceptionally conservative capital structure alongside rising profitability. A closer look at the consolidated performance figures outlines a highly optimized operational model:
- Revenue Scale: Total operational income grew consistently from ₹305 Crore in FY24 to ₹331 Crore in FY25 (registering a ~9% Year-on-Year increase). Performance indicators for 9M FY26 show an intake of ₹276 Crore, placing the company well on track to finish ahead of previous fiscal periods.
- Profitability Breakthrough: Profit After Tax (PAT) showed a massive leap, doubling from ₹12.2 Crore in FY24 to ₹24.4 Crore in FY25. Impressively, the company logged ₹27 Crore in net profits during just the first nine months of FY26, already outstripping its entire full-year profitability from FY25.
- Balance Sheet Health: A key highlighting factor for conservative retail investors is the company’s capital structure. Hexagon has tightly curbed institutional leverage, boasting an incredibly low Debt-to-Equity (D/E) ratio of just 0.18, which leaves minimal structural exposure to interest rate fluctuations.
Understanding the Key Risks & Strengths
- • Dynamic Revenue Mix: Splitting operations between B2B industrial supply, B2C premium brands, and institutional UN aid cushions single-market risk.
- • Profitability Momentum: Bottom-line growth outstripping overall revenue growth hints at rising company-wide scaling efficiencies.
- • Global Standards: Features deep operational compliance assets via FSSC 22000, ISO 9001:2015, and Halal-certified facilities.
- • 100% OFS Structure: Consists strictly of legacy promoters paring shares. No fresh cash infusions go directly back into company accounts.
- • Material Margins: Sourcing pure raw isolates without rigid long-term supplier agreements leaves margins vulnerable to trade spikes.
- • Muted Short-Term GMP: Initial gray market premiums track close to zero, suggesting lower near-term speculative interest.
IPO Timeline & Operational Roadmap
Investors applying for the issue should note these crucial dates:
- IPO Open Date: June 5, 2026
- IPO Close Date: June 9, 2026
- Basis of Allotment: June 10, 2026
- Credit of Shares / Refunds: June 11–12, 2026
- Expected Listing Date: Mid-June, 2026
Hexagon Nutrition stands out as a fundamentally solid, low-debt player entering the mainboard capital markets at an accessible price point (₹42–₹45 per share). The massive acceleration in PAT during FY25 and 9M FY26 signals a robust operational turnaround.
While the absolute lack of fresh equity deployment via the OFS structure and a muted initial GMP call for caution, long-term investors looking for a niche healthcare-meets-FMCG asset with strong global export roots will find the company’s financial profile worth serious consideration.
